



We are a biopharmaceutical company focused on making a powerful difference for patients, their caregivers and physicians by researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. For us, it's personal: By living up to our own potential, we are helping others live up to theirs.

OUR STRATEGY

Drive shareholder value by capitalizing on our defining strengths and generating high growth and profitability from our rare disease medicines

Successful and proven commercial execution that optimizes the growth trajectory of our acquired medicines

Uniquely strong in-house business development capability with a proven track record of execution

Growing pipeline of differentiated and clinically relevant medicines with a focus on rare diseases

Significantly Improved Growth



Recent Acquisitions

River Vision Development Corp.

May 2017

Added **teprotumumab**, a late-stage development biologic, to our clinical development pipeline

Raptor Pharmaceutical Corp.

October 2016

Added **PROCYSBI[®]** and **QUINSAIR[™]**, both rare disease medicines, to our Orphan business unit

Crealta Holdings LLC

January 2016

Added **KRYSTEXXA[®]**, a rare disease medicine for uncontrolled gout, to our Rheumatology business unit

Driving Additional Growth With Our Rare Disease Focused Pipeline

MEDICINE/ CANDIDATE	DESCRIPTION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	POST MARKET
● KRYSTEXXA [®]	• TRIPLE trial: tolerization and immunomodulation ^{(2)*} • RECIPE trial: immunomodulation ^{(3)*}	●
RAYOS [®]	• RIFLE trial: lupus*	●
● RAVICTI [®]	• Label expansion: birth to 2 months	●
● HZN-001 (teprotumumab) ⁽⁴⁾	• OPTIC trial	●	
● ACTIMMUNE [®]	• Combo solid tumor cancer therapy with Opdivo ^{®(5)*} • Combo CTCL therapy with Keytruda ^{®(6)*} • HER2+ breast cancer combo therapy ^{(7)*}	●	●	●	
● HZN-003	• Optimized uricase and optimized PEGylation for uncontrolled gout	●			
HZN-002	• Next-gen dexamethasone conjugate for inflammatory diseases	●			


● Rare Disease Medicine *Investigator-initiated trial

PROGRAMS NEW TO PIPELINE IN 2017

Purposeful Transition to Rare Disease Medicines Company


2013:

2 Medicines;
Net Sales of \$74M




2017:

11 Medicines, 6 for Rare Diseases;
Net Sales of \$1.06B



Rare Disease Medicines Are Driving Our Net Sales Growth

Rare Disease Medicines Now Make Up 60% of Net Sales



Rheumatology and Orphan Business Unit Annual Net Sales (\$M)

Executive Management

Timothy P. Walbert
Chairman, President and Chief Executive Officer

Brian K. Beeler
Executive Vice President, General Counsel

Robert F. Carey
Executive Vice President, Chief Business Officer

Michael A. DesJardin
Executive Vice President, Technical Operations

George P. Hampton
Executive Vice President, Primary Care Business Unit

Paul W. Hoelscher
Executive Vice President, Chief Financial Officer

Vikram Karnani
Executive Vice President, Chief Commercial Officer

David G. Kelly
Executive Vice President, Company Secretary and Managing Director, Ireland

Irina P. Konstantinovskiy
Executive Vice President, Chief Human Resources Officer

Shao-Lee Lin, M.D., Ph.D.
Executive Vice President, Head of R&D and Chief Scientific Officer

Eric B. Mosbrooker
Senior Vice President, Orphan Business Unit

Barry J. Moze
Executive Vice President, Chief Administrative Officer

Jeffrey W. Sherman, M.D., FACP
Executive Vice President, Chief Medical Officer

Board of Directors

Timothy P. Walbert
Chairman, President and Chief Executive Officer

Michael Grey
Lead Independent Director

Liam Daniel

Jeff Himawan, Ph.D.

Ronald Pauli

Gino Santini

James Shannon, M.D.

H. Thomas Watkins

Pascale Witz

Key Figures

2017 Net Sales: \$1.06B

Closing Share Price (3/29/18): \$14.20

Market Capitalization: \$2.3B

Ordinary Shares Outstanding (12/31/17): 163.1M

Global Employees (12/31/17): ~1,010

For safety information, see product websites:

www.ACTIMMUNE.com www.PENNSAID.com

For BUPHENYL: www.horizonpharma.com www.PROCYSBI.com

www.DUEXIS.com www.RAVICTI.com

www.KRYSTEXXA.com www.RAYOSrx.com

www.MIGEROT.com www.VIMOVO.com

Corporate Headquarters	U.S. Operations	Investor Relations Contacts		Corporate Media Contact	Ireland Media Contact
Connaught House, 1st Floor 1 Burlington Road Dublin 4, Ireland D04 C5Y6 +353 1 772 2100	150 S Saunders Road Lake Forest, IL 60045 +1 224 383 3000	Tina Ventura investor-relations@horizonpharma.com	Ruth Venning investor-relations@horizonpharma.com	Geoffrey Curtis media@horizonpharma.com	Ray Gordon ray@gordonmrm.ie

(1) Horizon Pharma estimate. (2) Immunomodulation arm expected to begin enrolling in 2018. (3) Trial expected to begin enrolling in 2018. (4) Teprotumumab is a fully human monoclonal antibody (mAb) IGF-1R inhibitor for moderate-to-severe thyroid eye disease (TED). (5) Registered trademark of Bristol-Myers Squibb. (6) Registered trademark of Merck. (7) Study with Taxol, Herceptin and Perjeta; Taxol is a registered trademark of Bristol-Myers Squibb. Herceptin and Perjeta are registered trademarks of Genentech. TRIPLE: Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect. RECIPE: REduCing Immunogenicity to Pegloticase. RIFLE: RAYOS (delayed release prednisone) Inhibits Fatigue in Lupus Erythematosus. OPTIC: Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study. CTCL: cutaneous T-cell lymphoma. HER2: human epidermal growth factor receptor 2.

This fact sheet is a summary of more detailed disclosure that can be found in Horizon's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Horizon's Form 10-K for the year ended December 31, 2017. The information in this fact sheet is given as of March 1, 2018, and Horizon does not undertake any obligation to update any information in this document.8